Ocrelizumab is noninferior to fingolimod, demonstrating efficacy and safety in children and adolescents with ...

Be ready for the possible transition from RRMS to SPMS by understanding new symptoms, treatment options, and what to discuss ...

Insights from ECTRIMS 2025, including anticipated presentations, key takeaways, and how emerging research on DMTs in RRMS may affect patient care.

Combining the diabetes medication metformin and the antihistamine clemastine increased myelin repair in people with RRMS, ...

New clinical trial data show children with MS may benefit as much from treatment with Ocrevus as Gilenya – and for some outcomes, more.

Dr Devon Conway describes how the upcoming conference is expected to provide important new data on the safety and real-world effectiveness of DMTs in RRMS.

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of ...

A recent study reveals that over one-third of individuals with relapsing-remitting multiple sclerosis (MS) do not fully recover from relapses, highlighting critical recovery factors. MS is one of the ...

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...